Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(-1.89%)
HKD 0.05
(-1.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.94 Million HKD | -98.8% |
| 2022 | 493.37 Million HKD | 6.32% |
| 2021 | 464.04 Million HKD | 5.99% |
| 2020 | 437.83 Million HKD | 2.07% |
| 2019 | 428.96 Million HKD | 3.84% |
| 2018 | 413.09 Million HKD | 5.27% |
| 2017 | 392.4 Million HKD | 18.99% |
| 2016 | 329.77 Million HKD | -8.66% |
| 2015 | 361.03 Million HKD | 383.73% |
| 2014 | -127.24 Million HKD | -669.63% |
| 2013 | 22.33 Million HKD | 130.48% |
| 2012 | -73.28 Million HKD | 52.68% |
| 2011 | -154.86 Million HKD | -6.57% |
| 2010 | -145.31 Million HKD | -38.41% |
| 2009 | -104.98 Million HKD | -30.07% |
| 2008 | -80.71 Million HKD | -11.75% |
| 2007 | -72.23 Million HKD | 8.53% |
| 2006 | -78.96 Million HKD | -83.34% |
| 2005 | -43.07 Million HKD | 26.17% |
| 2004 | -58.33 Million HKD | 17.41% |
| 2003 | -70.63 Million HKD | -26.03% |
| 2002 | -56.04 Million HKD | -88.53% |
| 2001 | -29.72 Million HKD | -486.24% |
| 2000 | -5.07 Million HKD | -168.77% |
| 1999 | 7.37 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 5.94 Million HKD | -98.8% |
| 2023 Q2 | 513.65 Million HKD | 0.0% |
| 2023 Q4 | 5.94 Million HKD | 0.0% |
| 2022 Q2 | 483.5 Million HKD | 0.0% |
| 2022 FY | 493.37 Million HKD | 6.32% |
| 2022 Q4 | 493.37 Million HKD | 0.0% |
| 2021 Q2 | 448.09 Million HKD | 0.0% |
| 2021 Q4 | 464.04 Million HKD | 0.0% |
| 2021 FY | 464.04 Million HKD | 5.99% |
| 2020 Q4 | 437.83 Million HKD | 0.0% |
| 2020 FY | 437.83 Million HKD | 2.07% |
| 2020 Q2 | 433.79 Million HKD | 0.0% |
| 2019 FY | 428.96 Million HKD | 3.84% |
| 2019 Q2 | 413.76 Million HKD | 0.0% |
| 2019 Q4 | 428.96 Million HKD | 0.0% |
| 2018 Q2 | -125.27 Million HKD | 0.0% |
| 2018 Q4 | -99.26 Million HKD | 0.0% |
| 2018 FY | 413.09 Million HKD | 5.27% |
| 2017 FY | 392.4 Million HKD | 18.99% |
| 2017 Q4 | -119.95 Million HKD | 0.0% |
| 2017 Q2 | -124.98 Million HKD | 0.0% |
| 2016 Q2 | -184 Million HKD | 0.0% |
| 2016 FY | 329.77 Million HKD | -8.66% |
| 2016 Q4 | -182.58 Million HKD | 0.0% |
| 2015 Q1 | -160.56 Million HKD | -26.19% |
| 2015 Q4 | -151.32 Million HKD | 0.0% |
| 2015 FY | 361.03 Million HKD | 383.73% |
| 2015 Q2 | -133.34 Million HKD | 16.96% |
| 2014 Q1 | -162.25 Million HKD | -826.34% |
| 2014 FY | -127.24 Million HKD | -669.63% |
| 2014 Q4 | -127.24 Million HKD | 16.41% |
| 2014 Q3 | -152.22 Million HKD | -318.86% |
| 2014 Q2 | -36.34 Million HKD | 77.6% |
| 2013 Q2 | -37.29 Million HKD | 75.72% |
| 2013 Q4 | 22.33 Million HKD | 121.54% |
| 2013 Q3 | -103.69 Million HKD | -178.08% |
| 2013 Q1 | -153.56 Million HKD | -17.72% |
| 2013 FY | 22.33 Million HKD | 130.48% |
| 2012 Q2 | -120 Million HKD | 4.76% |
| 2012 Q1 | -126 Million HKD | 18.64% |
| 2012 FY | -73.28 Million HKD | 52.68% |
| 2012 Q4 | -130.45 Million HKD | 4.4% |
| 2012 Q3 | -136.45 Million HKD | -13.7% |
| 2011 Q4 | -154.86 Million HKD | 0.0% |
| 2011 FY | -154.86 Million HKD | -6.57% |
| 2011 Q2 | -137.72 Million HKD | 0.0% |
| 2010 FY | -145.31 Million HKD | -38.41% |
| 2010 Q4 | -145.31 Million HKD | 0.0% |
| 2010 Q2 | -136.91 Million HKD | 0.0% |
| 2009 Q4 | -104.98 Million HKD | 0.0% |
| 2009 FY | -104.98 Million HKD | -30.07% |
| 2008 FY | -80.71 Million HKD | -11.75% |
| 2007 FY | -72.23 Million HKD | 8.53% |
| 2006 FY | -78.96 Million HKD | -83.34% |
| 2005 FY | -43.07 Million HKD | 26.17% |
| 2004 FY | -58.33 Million HKD | 17.41% |
| 2003 FY | -70.63 Million HKD | -26.03% |
| 2002 FY | -56.04 Million HKD | -88.53% |
| 2001 FY | -29.72 Million HKD | -486.24% |
| 2000 FY | -5.07 Million HKD | -168.77% |
| 1999 FY | 7.37 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 102.298% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 99.707% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 98.029% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 131.222% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 80.794% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 102.711% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 97.68% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 98.426% |
| SSY Group Limited | 1.71 Billion HKD | 99.653% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 180.335% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 98.239% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.988% |